Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial

被引：0

作者：

Paschke, R. ^{[1
]}

Brose, M. S. ^{[2
]}

Jarzab, B. ^{[3
,4
]}

Elisei, R. ^{[5
]}

Siena, S. ^{[6
]}

Bastholt, L. ^{[7
]}

de la Fouchardiere, C. ^{[8
]}

Pacini, F. ^{[9
]}

Nutting, C. ^{[10
]}

Shong, Y. K. ^{[11
]}

Sherman, S., I ^{[12
]}

Smit, J. W. A. ^{[13
]}

Chung, J. ^{[14
]}

Kappeler, C. ^{[15
]}

Molnar, I ^{[14
]}

Schlumberger, M. ^{[16
]}

机构：

[1] Univ Hosp Leipzig, Dept Endocrinol & Nephrol, Leipzig, Germany

[2] Univ Penn, Abramson Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA

[3] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland

[4] Inst Oncol, Gliwice, Poland

[5] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[6] Osped Niguarda Ca Granda, Milan, Italy

[7] Odense Univ Hosp, DK-5000 Odense, Denmark

[8] Hosp Civils Ctr Anticanc, Consortium Canc Thyroidien, Lyon, France

[9] Univ Siena, Unit Endocrinol, I-53100 Siena, Italy

[10] Royal Marsden Hosp, London SW3 6JJ, England

[11] Asan Med Ctr, Seoul, South Korea

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[13] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands

[14] Bayer HealthCare Pharmaceut, Montville, NJ USA

[15] Bayer Pharma AG, Berlin, Germany

[16] Inst Gustave Roussy, Villejuif, France

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V400

引用

页码：120 / 120

页数：1

共 50 条

[21] COST-EFFECTIVENESS OF SORAFENIB FOR TREATMENT OF RADIOACTIVE IODINE (RAI)-REFRACTORY LOCALLY ADVANCED/METASTATIC DIFFERENTIATED THYROID CANCER (DTC) IN TURKEY
Erdal, E.
Sayman, H.
Turkmen, C.
Aral, F.
Yildiz, O.
Okutur, K.
Parali, E.
Deger, C.
Tunalioglu, A.
Sar, C.
Asan, S.
Sumer, F.
Ozel, O.
VALUE IN HEALTH, 2015, 18 (03) : A203 - A204
[22] Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer The REALITY Randomized Clinical Trial
Lin, Yansong
Qin, Shukui
Li, Zhiyong
Yang, Hui
Fu, Wei
Li, Shaohua
Chen, Wenxin
Gao, Zairong
Miao, Weibing
Xu, Huiqin
Zhang, Qing
Zhao, Xinming
Bao, Jiandong
Li, Linfa
Ren, Yuan
Lin, Chenghe
Jing, Shanghua
Ma, Qingjie
Liang, Jun
Chen, Guang
Zhang, Hong
Zhang, Yifan
Zhou, Xianfeng
Sang, Yaxiong
Hou, Zhiguo
JAMA ONCOLOGY, 2022, 8 (02) : 242 - 250
[23] Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
Blair, Hannah A.
Plosker, Greg L.
TARGETED ONCOLOGY, 2015, 10 (01) : 171 - 178
[24] Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
Hannah A. Blair
Greg L. Plosker
Targeted Oncology, 2015, 10 : 171 - 178
[25] Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey
Majidova, Nargiz
Aghamaliyeva, Shahla
Guliyev, Murat
Dinc, Gulhan
Akyildiz, Arif
Ozcan, Erkan
Kahvecioglu, Fatma Akdag
Yildirim, Hasan Cagri
Sever, Nadiye
Guren, Ali Kaan
Kocaaslan, Erkam
Erel, Pinar
Agyol, Yesim
Celebi, Abdussamet
Arikan, Rukiye
Isik, Selver
Bayoglu, Ibrahim Vedat
Demirci, Nebi Serkan
Dizdar, Omer
Hacibekiroglu, Ilhan
Kostek, Osman
Sari, Murat
JOURNAL OF CHEMOTHERAPY, 2024,
[26] Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
Marcia S Brose
Christopher M Nutting
Steven I Sherman
Young Kee Shong
Johannes WA Smit
Gerhard Reike
John Chung
Joachim Kalmus
Christian Kappeler
Martin Schlumberger
BMC Cancer, 11
[27] Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
Brose, Marcia S.
Nutting, Christopher M.
Sherman, Steven I.
Shong, Young Kee
Smit, Johannes W. A.
Reike, Gerhard
Chung, John
Kalmus, Joachim
Kappeler, Christian
Schlumberger, Martin
BMC CANCER, 2011, 11
[28] A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer
Ji, Dongmei
Song, Lijie
Cheng, Ying
Shen, Weina
Kuang, Muyu
Chen, Jiaying
Yang, Minjie
Cui, Hongxia
Zhou, Jinghong
Shi, Haiyan
Tan, Panfeng
Fan, Songhua
Shi, Michael
Su, Weiguo
Ji, Qinghai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case
Silaghi, Cristina Alina
Stanoiu-Pinzariu, Oana
Silaghi, Horatiu
Piciu, Doina
Georgescu, Carmen Emanuela
ARCHIVE OF CLINICAL CASES, 2021, 8 (04): : 72 - 83
[30] Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.
Huillard, Olivier
Brose, Marcia S.
Jouinot, Anne
Tlemsani, Camille
Arrondeau, Jennifer
Meinhardt, Gerold
Fellous, Marc Mardoche
De Sanctis, Yoriko
Schlumberger, Martin
Goldwasser, Francois
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →